Cargando…

Construction and Validation of a UPR-Associated Gene Prognostic Model for Head and Neck Squamous Cell Carcinoma

Our study is aimed at constructing and validating a UPR-associated gene signature to predict HNSCC prognosis. We obtained 544 samples of RNA sequencing data and clinical characteristics from TCGA database and randomly grouped the samples into training and testing cohorts (1 : 1 ratio). After identif...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Tao, Chen, Lingling, Xie, Fuping, Lin, Shiqi, Lin, Yuhan, Chen, Jiamin, Liu, Huanhuan, Wu, Ye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9192238/
https://www.ncbi.nlm.nih.gov/pubmed/35707371
http://dx.doi.org/10.1155/2022/8677309
_version_ 1784726192392241152
author Wang, Tao
Chen, Lingling
Xie, Fuping
Lin, Shiqi
Lin, Yuhan
Chen, Jiamin
Liu, Huanhuan
Wu, Ye
author_facet Wang, Tao
Chen, Lingling
Xie, Fuping
Lin, Shiqi
Lin, Yuhan
Chen, Jiamin
Liu, Huanhuan
Wu, Ye
author_sort Wang, Tao
collection PubMed
description Our study is aimed at constructing and validating a UPR-associated gene signature to predict HNSCC prognosis. We obtained 544 samples of RNA sequencing data and clinical characteristics from TCGA database and randomly grouped the samples into training and testing cohorts (1 : 1 ratio). After identifying 14 UPR-associated genes with LASSO and univariate Cox regression analysis, HNSCC samples were categorized into low-risk (LR) and high-risk (HR) subgroups depending on the risk score. Our analyses indicated that low-risk patients had a much better prognosis in the training and testing cohorts. To predict the HNSCC prognosis with the 14 UPR-associated gene signatures, we incorporated the UPR gene risk score, N stage, M stage, and age into a nomogram model. We further explored the sensitivity to anticancer drugs by using the IC50 analysis in two subgroups from the Cancer Genome Project database. The outcomes showed that the AKT inhibitor III and sorafenib were sensitive anticancer drugs in HR and LR patients, respectively. The immune cell infiltration analysis and GSEA provided strong evidence for elucidating the molecular mechanisms of UPR-associated genes affecting HNSCC. In conclusion, the UPR-associated gene risk score, N stage, M stage, and age can serve as a robust model for predicting prognosis and can improve decision-making at the individual patient level.
format Online
Article
Text
id pubmed-9192238
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-91922382022-06-14 Construction and Validation of a UPR-Associated Gene Prognostic Model for Head and Neck Squamous Cell Carcinoma Wang, Tao Chen, Lingling Xie, Fuping Lin, Shiqi Lin, Yuhan Chen, Jiamin Liu, Huanhuan Wu, Ye Biomed Res Int Research Article Our study is aimed at constructing and validating a UPR-associated gene signature to predict HNSCC prognosis. We obtained 544 samples of RNA sequencing data and clinical characteristics from TCGA database and randomly grouped the samples into training and testing cohorts (1 : 1 ratio). After identifying 14 UPR-associated genes with LASSO and univariate Cox regression analysis, HNSCC samples were categorized into low-risk (LR) and high-risk (HR) subgroups depending on the risk score. Our analyses indicated that low-risk patients had a much better prognosis in the training and testing cohorts. To predict the HNSCC prognosis with the 14 UPR-associated gene signatures, we incorporated the UPR gene risk score, N stage, M stage, and age into a nomogram model. We further explored the sensitivity to anticancer drugs by using the IC50 analysis in two subgroups from the Cancer Genome Project database. The outcomes showed that the AKT inhibitor III and sorafenib were sensitive anticancer drugs in HR and LR patients, respectively. The immune cell infiltration analysis and GSEA provided strong evidence for elucidating the molecular mechanisms of UPR-associated genes affecting HNSCC. In conclusion, the UPR-associated gene risk score, N stage, M stage, and age can serve as a robust model for predicting prognosis and can improve decision-making at the individual patient level. Hindawi 2022-06-06 /pmc/articles/PMC9192238/ /pubmed/35707371 http://dx.doi.org/10.1155/2022/8677309 Text en Copyright © 2022 Tao Wang et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Wang, Tao
Chen, Lingling
Xie, Fuping
Lin, Shiqi
Lin, Yuhan
Chen, Jiamin
Liu, Huanhuan
Wu, Ye
Construction and Validation of a UPR-Associated Gene Prognostic Model for Head and Neck Squamous Cell Carcinoma
title Construction and Validation of a UPR-Associated Gene Prognostic Model for Head and Neck Squamous Cell Carcinoma
title_full Construction and Validation of a UPR-Associated Gene Prognostic Model for Head and Neck Squamous Cell Carcinoma
title_fullStr Construction and Validation of a UPR-Associated Gene Prognostic Model for Head and Neck Squamous Cell Carcinoma
title_full_unstemmed Construction and Validation of a UPR-Associated Gene Prognostic Model for Head and Neck Squamous Cell Carcinoma
title_short Construction and Validation of a UPR-Associated Gene Prognostic Model for Head and Neck Squamous Cell Carcinoma
title_sort construction and validation of a upr-associated gene prognostic model for head and neck squamous cell carcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9192238/
https://www.ncbi.nlm.nih.gov/pubmed/35707371
http://dx.doi.org/10.1155/2022/8677309
work_keys_str_mv AT wangtao constructionandvalidationofauprassociatedgeneprognosticmodelforheadandnecksquamouscellcarcinoma
AT chenlingling constructionandvalidationofauprassociatedgeneprognosticmodelforheadandnecksquamouscellcarcinoma
AT xiefuping constructionandvalidationofauprassociatedgeneprognosticmodelforheadandnecksquamouscellcarcinoma
AT linshiqi constructionandvalidationofauprassociatedgeneprognosticmodelforheadandnecksquamouscellcarcinoma
AT linyuhan constructionandvalidationofauprassociatedgeneprognosticmodelforheadandnecksquamouscellcarcinoma
AT chenjiamin constructionandvalidationofauprassociatedgeneprognosticmodelforheadandnecksquamouscellcarcinoma
AT liuhuanhuan constructionandvalidationofauprassociatedgeneprognosticmodelforheadandnecksquamouscellcarcinoma
AT wuye constructionandvalidationofauprassociatedgeneprognosticmodelforheadandnecksquamouscellcarcinoma